These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 7952799)

  • 41. [Inhibition of flecainide resorption by activated charcoal].
    Nitsch J; Köhler U; Lüderitz B
    Z Kardiol; 1987 May; 76(5):289-91. PubMed ID: 3113085
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effect of activated charcoal administration on acetylcysteine serum levels in humans.
    North DS; Peterson RG; Krenzelok EP
    Am J Hosp Pharm; 1981 Jul; 38(7):1022-4. PubMed ID: 7258201
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bioavailability and diuretic effect of furosemide following administration of tablets and retarded capsules to human subjects.
    Yagi N; Kiuchi T; Satoh H; Terashima Y; Kenmotsu H; Sekikawa H; Takada M
    Biol Pharm Bull; 1996 Apr; 19(4):616-22. PubMed ID: 8860970
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Influence of tablet dissolution on furosemide bioavailability: a bioequivalence study.
    McNamara PJ; Foster TS; Digenis GA; Patel RB; Craig WA; Welling PG; Rapaka RS; Prasad VK; Shah VP
    Pharm Res; 1987 Apr; 4(2):150-3. PubMed ID: 3509139
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug adsorption efficacy and palatability of a novel charcoal cookie formulation.
    Klein-Schwartz W; Doyon S; Dowling T
    Pharmacotherapy; 2010 Sep; 30(9):888-94. PubMed ID: 20795844
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Transport of furosemide into the intestinal lumen and the lack of effect of gastrointestinal dialysis by charcoal in rats with acute renal failure.
    Arimori K; Nakano M
    J Pharmacobiodyn; 1988 Jan; 11(1):1-8. PubMed ID: 3385600
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Kinetics of piretanide absorption from the gastrointestinal tract.
    Brockmeier D; Grigoleit HG; Heptner H; Meyer BH
    Methods Find Exp Clin Pharmacol; 1986 Dec; 8(12):731-9. PubMed ID: 3807474
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The influence of food intake on the effect of two controlled release formulations of furosemide.
    Paintaud G; Alván G; Eckernäs SA; Wakelkamp M; Grahnén A
    Biopharm Drug Dispos; 1995 Apr; 16(3):221-32. PubMed ID: 7787134
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evaluation of oral mucoadhesive microspheres in man on the basis of the pharmacokinetics of furosemide and riboflavin, compounds with limited gastrointestinal absorption sites.
    Akiyama Y; Nagahara N; Nara E; Kitano M; Iwasa S; Yamamoto I; Azuma J; Ogawa Y
    J Pharm Pharmacol; 1998 Feb; 50(2):159-66. PubMed ID: 9530983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inter-subject variability in intestinal drug solubility.
    Rabbie SC; Flanagan T; Martin PD; Basit AW
    Int J Pharm; 2015 May; 485(1-2):229-34. PubMed ID: 25758158
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Reversible adsorption of nicotinic acid onto charcoal in vitro.
    Roivas L; Neuvonen PJ
    J Pharm Sci; 1992 Sep; 81(9):917-9. PubMed ID: 1432640
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Absorption and disposition of furosemide in congestive heart failure.
    Brater DC; Seiwell R; Anderson S; Burdette A; Dehmer GJ; Chennavasin P
    Kidney Int; 1982 Aug; 22(2):171-6. PubMed ID: 7132061
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Bioavailability of furosemide in right cardiac insufficiency].
    Schlicker E
    Dtsch Med Wochenschr; 1995 Apr; 120(15):540. PubMed ID: 7720537
    [No Abstract]   [Full Text] [Related]  

  • 54. A study on furosemide disposition in man.
    Zhu JB; Koizumi T
    J Pharmacobiodyn; 1987 Aug; 10(8):370-6. PubMed ID: 3694431
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Polymeric microcontainers improve oral bioavailability of furosemide.
    Nielsen LH; Melero A; Keller SS; Jacobsen J; Garrigues T; Rades T; Müllertz A; Boisen A
    Int J Pharm; 2016 May; 504(1-2):98-109. PubMed ID: 27033999
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Formulation and in vitro examination of furosemide containing suppositories and preliminary experiences of their clinical use.
    Regdon G; Fazekas T; Regdon G; Selmeczi B
    Pharmazie; 1996 Feb; 51(2):116-9. PubMed ID: 8720807
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Implications of intraindividual variability in bioavailability studies of furosemide.
    Grahnén A; Hammarlund M; Lundqvist T
    Eur J Clin Pharmacol; 1984; 27(5):595-602. PubMed ID: 6519165
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Improvement in site-specific intestinal absorption of furosemide by Eudragit L100-55.
    Terao T; Matsuda K; Shouji H
    J Pharm Pharmacol; 2001 Apr; 53(4):433-40. PubMed ID: 11341359
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of five activated charcoal formulations for inhibition of aspirin absorption and palatability in man.
    Scholtz EC; Jaffe JM; Colaizzi JL
    Am J Hosp Pharm; 1978 Nov; 35(11):1355-9. PubMed ID: 707504
    [No Abstract]   [Full Text] [Related]  

  • 60. Do gastric contents modify antidotal efficacy of oral activated charcoal?
    Olkkola KT; Neuvonen PJ
    Br J Clin Pharmacol; 1984 Nov; 18(5):663-9. PubMed ID: 6508975
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.